Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees
Anavex Life Sciences Corp., a Nasdaq-listed clinical-stage biopharmaceutical company focused on CNS disorders, has mailed a letter to stockholders urging a vote "FOR" all six of its director nominees in the upcoming 2026 Annual Meeting. The letter highlights the nominees' diverse expertise in finance, clinical research, drug development, and health…